Coeptis (BHSE) raises cash, grows NexGenAI revenue but posts big losses, going concern

Coeptis Therapeutics Holdings, Inc. (NASDAQ: BHSE) - Quick internal snapshot

Short take: management is pushing the biotech R&D roadmap (GEAR, SNAP‑CAR) while building a small revenue stream from the NexGenAI technology platform. The company strengthened its balance sheet via equity financings and debt conversions but continues to burn cash and reports a material going‑concern warning.

Key facts & figures (as reported June 30, 2025)

* Cash: $1,996,726 (Dec 31, 2024: $532,885)

* Total assets: $12,191,479 (Dec 31, 2024: $8,908,660)

* Investments (private holdings): $6,941,083

* Marketable securities: $990,566 (unrealized gain recorded: $390,566)

* Customer deposits: $1,631,445

* Total liabilities: $5,111,349

* Convertible notes payable (net): $1,042,007

* Notes payable - current portion in default: $100,000

* Warrant liabilities (fair value): $467,250 (Public $216,000; Private $251,250)

* Stockholders' equity (total): $7,080,130 (controlling interest $6,095,830; noncontrolling $984,300)

* Shares outstanding (reported Aug 13, 2025): 4,820,317

Income statement - headline operating numbers (periods ended June 30, 2025)

* Revenue: $200,681 (Q2 2025) - $263,555 (YTD 6‑month)

* Gross profit: $155,524 (Q2) - $173,242 (YTD)

* Total cost of operations: $4,676,738 (Q2) - $8,751,440 (YTD)

* Loss from operations: $(4,521,214) (Q2) - $(8,578,198) (YTD)

* Total other income (net): $186,628 (Q2) - $822,671 (YTD)

* Net loss: $(4,334,586) (Q2) - $(7,755,527) (YTD)

* Net loss attributable to common stockholders (YTD): $(6,592,325)

* Loss per share (basic & diluted): $(1.17) (Q2) - $(2.29) (YTD)

* Weighted average shares (YTD): 3,391,685

What's happening inside the company - operational & corporate highlights

* Strategic focus: dual operating segments - Biotechnology (GEAR, SNAP‑CAR, Deverra/Vy‑Gen assets) and Technology (NexGenAI platform). Biotech is pre‑revenue; Technology produced the small sales reported in 2025.

* Licensing & IP: March 2025 exclusive worldwide license for the GEAR™ platform from Vy‑Gen (license fees, milestones, royalties expected).

* Asset moves: acquired NexGenAI platform (Dec 2024) and invested in private‑company shares (recorded as investments).

* Financing activity: completed Series A preferred offering (aggregate $10.0M round completed Feb 6, 2025); Yorkville SEPA and convertible note activity - several conversions of Yorkville notes into equity during 2025 (reducing debt balances).

* Corporate actions: 20‑for‑1 reverse split applied retrospectively (Dec 31, 2024) and ongoing private placements announced (subsequent events: July 11, 2025 offering; Yorkville conversion July 14, 2025).

Positive aspects of the income statement / financial position

* Revenue traction: Technology segment has begun to generate revenue - $263,555 YTD and gross profit recorded (shows product/service commercial activity beyond pure R&D).

* Improved liquidity vs. prior year: cash rose to ~$2.0M due to financing (net cash provided by financing activities $6,226,750 YTD).

* Balance sheet strengthening: total assets up to $12.19M; equity increased to $7.08M driven by financings and debt conversions.

* Realized mark‑to‑market benefit: unrealized gain on marketable securities $390,566 and favorable fair value changes on certain derivative instruments contributed to other income (helped reduce reported loss before tax).

Negative aspects / risks from the income statement and notes

* Large operating losses: $8.58M loss from operations YTD - operating expenses (professional services $5.3M YTD, stock‑based comp $788k, R&D still material) far exceed revenue.

* Cash burn: operating cash used $(4.76M) in six months - company remains financing‑dependent to fund operations.

* Accumulated deficit & going concern: accumulated deficit $105,989,201; the filing explicitly states substantial doubt about the company's ability to continue as a going concern without additional capital.

* Customer concentration: advertising/webinar revenue recognized from only three and two customers respectively - high revenue concentration and customer risk.

* Debt & default risk: notes payable include a current portion in default ($100,000) and multiple convertible note arrangements with complex amortization/conversion mechanics (SEPA and Yorkville facilities) that can dilute common holders.

* Warrant & derivative liabilities: warrants are accounted for as liabilities and are marked to market (total warrant liabilities $467,250); these instruments create earnings volatility and potential future cash/stock settlement dynamics.

What to watch next (near term catalysts / risks)

* Financing activity - success of the July 2025 private placement and further Yorkville advances or conversions (management intends to raise additional capital).

* Execution on GEAR and SNAP‑CAR development milestones and any partnering or milestone payments - these could materially change cash needs and valuation.

* Revenue ramp from NexGenAI / recurring customer wins and reduction in customer concentration.

* Any further debt defaults, new amortization events under Yorkville notes or share issuance that could accelerate dilution.

Bottom line: Coeptis (NASDAQ: BHSE) is transitioning from pure R&D toward a two‑track model (biotech R&D + small technology revenue). The company has improved cash via financings and converted debt to equity, but operating losses, cash burn, a large accumulated deficit and concentrated revenue mean it remains highly capital‑dependent and risky until meaningful product revenues, partnerships, or sustained financing are secured.